MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Revenue of MediciNova, Inc. (MNOV)
Revenue in 2023 (TTM): $1000 K
According to MediciNova, Inc.'s latest financial reports the company's current revenue (TTM) is $1000 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MediciNova, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1000 K | $979.71 K | $-9,879,970 | $-8,568,469 | $-8,571,516 |
| 2022 | $ | $-212,426 | $-13,853,830 | $-14,066,261 | $-14,069,083 |
| 2021 | $4.04 M | $4.04 M | $-10,189,663 | $-10,131,684 | $-10,134,252 |
| 2020 | $ | $-21,342 | $-14,156,981 | $-13,855,545 | $-13,853,897 |
| 2019 | $ | $-23,944 | $-14,007,133 | $-12,928,998 | $-12,941,658 |
| 2018 | $ | $-25,881 | $-15,560,945 | $-14,669,811 | $-14,675,087 |
| 2017 | $ | $-28,098 | $-12,998,995 | $-12,907,186 | $-11,163,136 |
| 2016 | $ | $-14,127 | $-10,867,707 | $-10,862,225 | $-10,865,979 |
| 2015 | $ | $-26,704 | $-8,795,682 | $-8,837,720 | $-8,845,079 |
| 2014 | $ | $ | $-9,182,825 | $-9,199,264 | $-9,195,292 |
| 2013 | $6 M | $6 M | $-3,924,002 | $-4,024,493 | $-4,028,528 |
| 2012 | $802.58 K | $802.58 K | $-10,880,638 | $-10,950,170 | $-10,961,314 |
| 2011 | $ | $ | $-16,085,545 | $-17,722,503 | $-17,734,076 |
| 2010 | $ | $ | $-19,083,499 | $-20,174,630 | $-20,187,308 |
| 2009 | $ | $ | $-20,142,679 | $-20,361,883 | $-20,368,890 |
| 2008 | $ | $ | $-21,606,253 | $-21,911,270 | $-21,924,829 |
| 2007 | $263.88 M | $117.27 M | $-48,367,231 | $-48,883,244 | $-48,903,244 |
| 2006 | $263.88 K | $117.27 K | $-41,677,533 | $-35,689,611,000 | $-35,689,611 |
| 2005 | $804.07 K | $129.84 K | $-25,539,681 | $-25,692,135,000 | $-25,692,135 |
| 2004 | $490.28 K | $52.7 K | $-48,227,308 | $-48,272,603,000 | $-48,272,603 |
| 2003 | $ | $ | $-6,283,204 | $-6,209,130 | $-6,209,130 |
| 2002 | $ | $ | $-7,095,000 | $-6,931,000 | $-6,931,000 |
| 2001 | $ | $ | $-2,015,000 | $ | $-1,795,000 |